Plant Name: Saxifraga stolonifera
Taxonomic Information:
Plant ID: NPO19728
Plant Latin Name: Saxifraga stolonifera
Taxonomy Genus: Saxifraga
Taxonomy Family: Saxifragaceae
Plant External Links:
NCBI TaxonomyDB:
182070
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
ChinaTraditional Medicine System:
TCMMedicinal Functions:
Antibacterial; Antiphlogistic; Depurative; Febrifuge
Geographical Distribution:
China
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; | |
| TDP1; BLM; ALOX12; HSD17B10; NOX4; POLB; | |
| FYN; MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; | |
| CA2; CA12; CA14; CA7; CA4; CA6; | |
| KDM4E; | |
| MMP9; MMP1; MMP2; | |
| NFKB1; | |
| FUT7; | |
| LMNA; FABP4; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | FYN | Tyrosine-protein kinase FYN | P06241 | CHEMBL1841 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.608E-14 | 1.657E-09 | CA12, CA14, CA2, CA4, CA6, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.036E-10 | 7.522E-07 | CA12, CA14, CA2, CA4, CA6, CA7 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.848E-09 | 1.290E-05 | CA12, CA2, CA4, CA6, CA7 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 9.706E-08 | 1.112E-04 | ALOX12, AURKB, AXL, CDK1, FYN, IGF1R, KDR, LMNA, MMP9, NFKB1, PIM1 |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 8.275E-07 | 6.436E-04 | AXL, BLM, CA2, CDK1, CYP1B1, FABP4, KDR, MMP9 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 3.828E-06 | 2.033E-03 | BLM, FYN, IGF1R, MMP2, NFKB1, NOX4, TSHR |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 6.149E-06 | 2.911E-03 | BLM, CA12, CA2, CA4, CA6, CA7, MMP1, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 8.482E-06 | 3.694E-03 | CA2, CA7 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 1.241E-05 | 4.827E-03 | ALOX12, CDK1, FLT3, IGF1R, KDR, MMP2, MMP9, PIM1, TSHR |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 1.610E-05 | 5.749E-03 | AXL, FYN, IGF1R |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.562E-05 | 8.491E-03 | CA2, CA7, FYN, KDR, NPSR1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.524E-13 | 1.905E-11 | CA12, CA2, CA4, CA7, CA6, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 3.151E-06 | 1.970E-04 | FLT3, MMP1, MMP2, MET, MMP9, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.931E-05 | 6.036E-04 | MMP2, KDR, MMP9, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.081E-05 | 4.502E-04 | FLT3, MMP9, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 4.180E-05 | 1.045E-03 | MMP1, MMP2, MMP9 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.127E-04 | 2.104E-03 | FLT3, PIM1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.178E-04 | 2.104E-03 | PIM1, CYP1B1, MMP9, MET, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 3.286E-04 | 4.563E-03 | KDR, FYN, MET, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 2.449E-04 | 3.827E-03 | FYN, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 5.107E-04 | 6.384E-03 | KDR, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 6.109E-04 | 6.809E-03 | MMP2, PIM1, NFKB1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 6.536E-04 | 6.809E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| NA: NA | Edema | NA | CA2; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; MMP9; MMP2; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; MMP9; MMP2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
